• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

立体定向消融体部放射治疗与传统分割放射治疗用于早期肺大细胞神经内分泌癌的比较

Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung.

作者信息

Wegner Rodney E, Abel Stephen, Colonias Athanasios

机构信息

Division of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA 15212, USA.

出版信息

Lung Cancer Manag. 2020 Apr 21;9(3):LMT32. doi: 10.2217/lmt-2020-0004.

DOI:10.2217/lmt-2020-0004
PMID:32774465
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7399604/
Abstract

AIM

Some patients with early stage large cell neuroendocrine carcinoma (LCNEC) of the lung are not surgical candidates and will be managed with radiotherapy. We used the national cancer database to identify predictors of stereotactic radiotherapy and compare outcomes.

MATERIALS & METHODS: We queried national cancer database for T1-2N0 LCNEC treated with radiation. Logistic regression and Cox regression identified predictors of stereotactic ablative body radiotherapy (SABR) and survival, respectively.

RESULTS

We identified 754 patients, with 238 (32%) treated with SABR. Predictors of SABR were distance to facility, no chemotherapy, academic center, T1 and recent year. After propensity matching, median survival was 34.7 months compared with 23.7 months in favor of SABR (p = 0.02).

CONCLUSION

SABR for LCNEC has increased over time and was associated with improved survival.

摘要

目的

一些早期肺大细胞神经内分泌癌（LCNEC）患者不适合手术，将接受放射治疗。我们利用国家癌症数据库确定立体定向放射治疗的预测因素并比较疗效。

材料与方法

我们在国家癌症数据库中查询接受放疗的T1-2N0 LCNEC患者。逻辑回归和Cox回归分别确定立体定向消融体部放疗（SABR）和生存的预测因素。

结果

我们确定了754例患者，其中238例（32%）接受了SABR治疗。SABR的预测因素为与医疗机构的距离、未接受化疗、学术中心、T1期和近年。倾向匹配后，SABR组的中位生存期为34.7个月，而另一组为23.7个月，SABR组更具优势（p = 0.02）。

结论

随着时间的推移，LCNEC的SABR治疗有所增加，且与生存期改善相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/7399604/0d498e7dcce3/lmt-09-32-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/7399604/1a8ec2caa1ad/lmt-09-32-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/7399604/0d498e7dcce3/lmt-09-32-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/7399604/1a8ec2caa1ad/lmt-09-32-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/7399604/0d498e7dcce3/lmt-09-32-g2.jpg

相似文献

1
Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung.立体定向消融体部放射治疗与传统分割放射治疗用于早期肺大细胞神经内分泌癌的比较
Lung Cancer Manag. 2020 Apr 21;9(3):LMT32. doi: 10.2217/lmt-2020-0004.
2
Stereotactic ablative radiation therapy versus conventionally fractionated radiation therapy for stage I small cell lung cancer.立体定向消融放疗与常规分割放疗治疗局限期小细胞肺癌的比较。
Radiother Oncol. 2019 Feb;131:145-149. doi: 10.1016/j.radonc.2018.12.006. Epub 2018 Dec 31.
3
Surgical resection versus stereotactic body radiation therapy in early stage bronchopulmonary large cell neuroendocrine carcinoma.手术切除与立体定向体部放疗治疗早期支气管肺大细胞神经内分泌癌。
Thorac Cancer. 2020 Feb;11(2):305-310. doi: 10.1111/1759-7714.13260. Epub 2019 Dec 20.
4
Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.立体定向消融体部放射治疗与根治性放射治疗：Ⅰ期肺癌真实世界结局比较。
Clin Oncol (R Coll Radiol). 2019 Oct;31(10):681-687. doi: 10.1016/j.clon.2019.07.013. Epub 2019 Jul 31.
5
Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis.立体定向体部放疗或立体定向消融放疗与手术治疗T1-3N0M0期非小细胞肺癌患者的疗效比较：一项系统评价和荟萃分析
Onco Targets Ther. 2017 Jun 7;10:2885-2892. doi: 10.2147/OTT.S138701. eCollection 2017.
6
Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.立体定向消融放疗（SABR）治疗早期非小细胞肺癌：腺癌和鳞癌生存结局比较。
Lung Cancer. 2019 Feb;128:127-133. doi: 10.1016/j.lungcan.2018.12.022. Epub 2018 Dec 24.
7
Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.立体定向体部放疗与常规分割放疗治疗早期非小细胞肺癌的比较。
Radiother Oncol. 2018 Nov;129(2):264-269. doi: 10.1016/j.radonc.2018.07.008. Epub 2018 Jul 18.
8
A Population-based Study of the Effectiveness of Stereotactic Ablative Radiotherapy Versus Conventional Fractionated Radiotherapy for Clinical Stage I Non-small Cell Lung Cancer Patients.一项基于人群的关于立体定向消融放疗与传统分割放疗对临床I期非小细胞肺癌患者有效性的研究。
Radiol Oncol. 2017 Dec 7;52(2):181-188. doi: 10.1515/raon-2017-0058. eCollection 2018 Jun.
9
Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy.关于 I 期非小细胞肺癌的进一步数据：手术与立体定向消融放疗的比较。
Ann Transl Med. 2015 Aug;3(13):172. doi: 10.3978/j.issn.2305-5839.2015.07.26.
10
Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid.立体定向体部放射治疗与分割放射治疗用于早期支气管肺类癌的比较。
Lung Cancer Manag. 2019 Aug 21;8(3):LMT14. doi: 10.2217/lmt-2019-0003.

引用本文的文献

1
Small cell lung cancer and neuroendocrine tumours.小细胞肺癌和神经内分泌肿瘤。
Breathe (Sheff). 2024 Nov 12;20(3):240004. doi: 10.1183/20734735.0004-2024. eCollection 2024 Oct.
2
Management of Large Cell Neuroendocrine Carcinoma.大细胞神经内分泌癌的管理
Front Oncol. 2021 Aug 27;11:653162. doi: 10.3389/fonc.2021.653162. eCollection 2021.
3
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities.肺大细胞神经内分泌癌：当前的治疗选择及未来潜在机遇

本文引用的文献

1
Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.Ⅰ期无法手术的小细胞肺癌行立体定向体部放疗（SBRT）后的临床结局：RSSearch 患者注册研究的多机构分析。
Am J Clin Oncol. 2019 Jul;42(7):602-606. doi: 10.1097/COC.0000000000000561.
2
Stereotactic body radiation therapy for pulmonary large cell neuroendocrine carcinoma: a case report.立体定向体部放射治疗肺大细胞神经内分泌癌：一例报告
Onco Targets Ther. 2019 Feb 18;12:1359-1364. doi: 10.2147/OTT.S189858. eCollection 2019.
3
Front Oncol. 2021 Apr 15;11:650293. doi: 10.3389/fonc.2021.650293. eCollection 2021.
Stereotactic ablative radiation therapy versus conventionally fractionated radiation therapy for stage I small cell lung cancer.
立体定向消融放疗与常规分割放疗治疗局限期小细胞肺癌的比较。
Radiother Oncol. 2019 Feb;131:145-149. doi: 10.1016/j.radonc.2018.12.006. Epub 2018 Dec 31.
4
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.立体定向消融放疗与标准放疗治疗Ⅰ期非小细胞肺癌（TROG 09.02 CHISEL）：一项 III 期、开放性标签、随机对照临床试验。
Lancet Oncol. 2019 Apr;20(4):494-503. doi: 10.1016/S1470-2045(18)30896-9. Epub 2019 Feb 12.
5
Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.立体定向体部放疗与常规分割放疗治疗早期非小细胞肺癌的比较。
Radiother Oncol. 2018 Nov;129(2):264-269. doi: 10.1016/j.radonc.2018.07.008. Epub 2018 Jul 18.
6
Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).立体定向体部放疗（SBRT）与常规分割放疗相比，可提高Ⅰ期非小细胞肺癌（NSCLC）的局部控制率和总生存率。
Acta Oncol. 2018 Nov;57(11):1567-1573. doi: 10.1080/0284186X.2018.1481292. Epub 2018 Jun 6.
7
The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung.系统治疗在Ⅰ期大细胞神经内分泌肺癌治疗中的作用。
J Thorac Oncol. 2018 May;13(5):707-714. doi: 10.1016/j.jtho.2018.01.019. Epub 2018 Jan 31.
8
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
9
SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.SPACE - 立体定向体部放疗与传统分割放疗治疗医学上无法手术的Ⅰ期非小细胞肺癌的随机研究
Radiother Oncol. 2016 Oct;121(1):1-8. doi: 10.1016/j.radonc.2016.08.015. Epub 2016 Sep 3.
10
Large-cell neuroendocrine carcinoma: controversies in diagnosis and treatment.大细胞神经内分泌癌：诊断与治疗中的争议。
J Natl Compr Canc Netw. 2011 Oct;9(10):1122-9. doi: 10.6004/jnccn.2011.0093.